Response to letter to the Editors—Safety of long-term denosumab therapy

Alison T. Stopeck; Douglas J. Warner

doi:10.1007/s00520-016-3492-8

Response to letter to the Editors—Safety of long-term denosumab therapy

Alison T. Stopeck, Douglas J. Warner

Cancer Center

Research output: Contribution to journal › Letter › peer-review

14 Scopus citations

Original language	English (US)
Pages (from-to)	353-355
Number of pages	3
Journal	Supportive Care in Cancer
Volume	25
Issue number	2
DOIs	https://doi.org/10.1007/s00520-016-3492-8
State	Published - Feb 1 2017

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s00520-016-3492-8

Cite this

@article{1c20c04516fd4edf934e8347cd0b1485,

title = "Response to letter to the Editors—Safety of long-term denosumab therapy",

author = "Stopeck, {Alison T.} and Warner, {Douglas J.}",

note = "Funding Information: Alison Stopeck (MD) served as a consultant for Amgen Inc., Pfizer, Bayer, Genentech, and Clovis Pharmaceuticals. She received research funding from Amgen Inc., Novartis, Peregrine, Puma, and Bayer. Douglas Warner (MD) is an Amgen Inc. employee and has received Amgen Inc. stocks. Funding Information: This work was supported by Amgen Inc. On behalf of Amgen Inc., Li Zhu (PhD) and Albert Rhee (PhD) provided biostatistical and medical writing support, respectively. ",

year = "2017",

month = feb,

day = "1",

doi = "10.1007/s00520-016-3492-8",

language = "English (US)",

volume = "25",

pages = "353--355",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Response to letter to the Editors—Safety of long-term denosumab therapy

AU - Stopeck, Alison T.

AU - Warner, Douglas J.

N1 - Funding Information: Alison Stopeck (MD) served as a consultant for Amgen Inc., Pfizer, Bayer, Genentech, and Clovis Pharmaceuticals. She received research funding from Amgen Inc., Novartis, Peregrine, Puma, and Bayer. Douglas Warner (MD) is an Amgen Inc. employee and has received Amgen Inc. stocks. Funding Information: This work was supported by Amgen Inc. On behalf of Amgen Inc., Li Zhu (PhD) and Albert Rhee (PhD) provided biostatistical and medical writing support, respectively.

PY - 2017/2/1

Y1 - 2017/2/1

UR - http://www.scopus.com/inward/record.url?scp=84996844647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996844647&partnerID=8YFLogxK

U2 - 10.1007/s00520-016-3492-8

DO - 10.1007/s00520-016-3492-8

M3 - Letter

C2 - 27885467

AN - SCOPUS:84996844647

SN - 0941-4355

VL - 25

SP - 353

EP - 355

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 2

ER -

Response to letter to the Editors—Safety of long-term denosumab therapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this